April 14, 2020 –
Calculating and interpreting success rates is extremely complex and requires a deep understanding of drug development and risk. This session outlines some of the essentials that go into a robust assessment of success based on our long history measuring, evaluating and developing more nuanced risk based performance models. The session identifies a variety of ways to measure success rates and how various aspects of performance including licensing and acquisition along with divestiture can bias results. Companies that want an unbiased and unvarnished assessment of their performance come to KMR as their trusted data source and analytics partner.